Neil S Sheerin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4187967/publications.pdf

Version: 2024-02-01

86	4,097	147566 31	118652 62
papers	citations	h-index	g-index

130	130	130	4912
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Dialysis or not? A comparative survival study of patients over 75 years with chronic kidney disease stage 5. Nephrology Dialysis Transplantation, 2007, 22, 1955-1962.	0.4	537
2	Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney International, 2015, 87, 1061-1073.	2.6	342
3	KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. Transplantation, 2020, 104, S11-S103.	0.5	306
4	Influence of Donor C3 Allotype on Late Renal-Transplantation Outcome. New England Journal of Medicine, 2006, 354, 2014-2023.	13.9	176
5	C3a Mediates Epithelial-to-Mesenchymal Transition in Proteinuric Nephropathy. Journal of the American Society of Nephrology: JASN, 2009, 20, 593-603.	3.0	118
6	Pivotal role of CD4+ T cells in renal fibrosis following ureteric obstruction. Kidney International, 2010, 78, 351-362.	2.6	118
7	Apical Proteins Stimulate Complement Synthesis by Cultured Human Proximal Tubular Epithelial Cells. Journal of the American Society of Nephrology: JASN, 1999, 10, 69-76.	3.0	108
8	Trajectories of Illness in Stage 5 Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1580-1590.	2.2	101
9	Synthesis of complement protein C3 in the kidney is an important mediator of local tissue injury. FASEB Journal, 2008, 22, 1065-1072.	0.2	84
10	Epithelial secretion of C3 promotes colonization of the upper urinary tract by Escherichia coli. Nature Medicine, 2001, 7, 801-806.	15.2	83
11	Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study. BMC Nephrology, 2019, 20, 125.	0.8	77
12	Summary of the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. Transplantation, 2020, 104, 708-714.	0.5	73
13	TNF-Î± regulation of C3 gene expression and protein biosynthesis in rat glomerular endothelial cells. Kidney International, 1997, 51, 703-710.	2.6	65
14	An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy. Kidney International, 2015, 88, 1314-1322.	2.6	58
15	Inhibition of lysosomal protease cathepsin D reduces renal fibrosis in murine chronic kidney disease. Scientific Reports, 2016, 6, 20101.	1.6	58
16	CD46 (Membrane Cofactor Protein) Acts as a Human Epithelial Cell Receptor for Internalization of Opsonized UropathogenicEscherichia coli. Journal of Immunology, 2006, 177, 2543-2551.	0.4	54
17	Minireview: Functions of the renal tract epithelium in coordinating the innate immune response to infection. Kidney International, 2004, 66, 1334-1344.	2.6	53
18	Mutations in mitochondrial DNA causing tubulointerstitial kidney disease. PLoS Genetics, 2017, 13, e1006620.	1.5	52

#	Article	IF	Citations
19	Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland. Kidney International, 2017, 92, 1261-1271.	2.6	49
20	Successful medical treatment of acute bilateral emphysematous pyelonephritis. American Journal of Kidney Diseases, 2000, 36, 1267-1270.	2.1	47
21	Deficiency of C4 from Donor or Recipient Mouse Fails to Prevent Renal Allograft Rejection. American Journal of Pathology, 2006, 168, 1241-1248.	1.9	47
22	Long- and short-term outcomes in renal allografts with deceased donors: A large recipient and donor genome-wide association study. American Journal of Transplantation, 2018, 18, 1370-1379.	2.6	47
23	Novel delivery of cellular therapy to reduce ischemia reperfusion injury in kidney transplantation. American Journal of Transplantation, 2021, 21, 1402-1414.	2.6	46
24	Successful Treatment of De Novo Posttransplant Thrombotic Microangiopathy With Eculizumab. Transplantation, 2011, 92, e42-e43.	0.5	45
25	Ubiquitin C-terminal hydrolase 1: A novel functional marker for liver myofibroblasts and a therapeutic target in chronic liver disease. Journal of Hepatology, 2015, 63, 1421-1428.	1.8	41
26	Mechanisms of Disease: the complement system in renal injuryâ€"new ways of looking at an old foe. Nature Clinical Practice Nephrology, 2007, 3, 277-286.	2.0	37
27	Illness trajectories: an important concept in the management of kidney failure. Nephrology Dialysis Transplantation, 2008, 23, 3746-3748.	0.4	37
28	Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with aHUS. Molecular Immunology, 2012, 49, 640-648.	1.0	37
29	A urinary microRNA panel that is an early predictive biomarker of delayed graft function following kidney transplantation. Scientific Reports, 2019, 9, 3584.	1.6	36
30	Regulation of Chemokine Function: The Roles of GAG-Binding and Post-Translational Nitration. International Journal of Molecular Sciences, 2017, 18, 1692.	1.8	34
31	Long-term outcomes and response to treatment in diacylglycerol kinase epsilon nephropathy. Kidney International, 2020, 97, 1260-1274.	2.6	31
32	Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooledpost hocanalysis. Transplant International, 2017, 30, 1275-1283.	0.8	30
33	The classical complement pathway plays a critical role in the opsonisation of uropathogenic Escherichia coli. Molecular Immunology, 2008, 45, 954-962.	1.0	28
34	CCL2 nitration is a negative regulator of chemokine-mediated inflammation. Scientific Reports, 2017, 7, 44384.	1.6	28
35	Synergy between type 1 fimbriae expression and C3 opsonisation increases internalisation of E. coli by human tubular epithelial cells. BMC Microbiology, 2009, 9, 64.	1.3	26
36	The role of complement in kidney disease. Clinical Medicine, 2020, 20, 156-160.	0.8	26

#	Article	IF	Citations
37	Lysosomal protease cathepsin D; a new driver of apoptosis during acute kidney injury. Scientific Reports, 2016, 6, 27112.	1.6	24
38	Ischaemia reperfusion injury: mechanisms of progression to chronic graft dysfunction. Pediatric Nephrology, 2019, 34, 951-963.	0.9	23
39	Haemolytic uremic syndrome: diagnosis and management. F1000Research, 2019, 8, 1690.	0.8	23
40	Accumulation of Immune Complexes in Glomerular Disease Is Independent of Locally Synthesized C3. Journal of the American Society of Nephrology: JASN, 2006, 17, 686-696.	3.0	21
41	Prognosis and management of chronic kidney disease (CKD) at the end of life. Postgraduate Medical Journal, 2014, 90, 98-105.	0.9	21
42	Computerized clinical decision support for the early recognition and management of acute kidney injury: a qualitative evaluation of end-user experience. CKJ: Clinical Kidney Journal, 2016, 9, 57-62.	1.4	20
43	Complement polymorphisms: Geographical distribution and relevance to disease. Immunobiology, 2012, 217, 265-271.	0.8	19
44	A Câ€terminal <scp>CXCL</scp>8 peptide based on chemokineâ€“glycosaminoglycan interactions reduces neutrophil adhesion and migration during inflammation. Immunology, 2019, 157, 173-184.	2.0	19
45	The methyltransferase SET9 regulates TGF B-1 activation of renal fibroblasts via interaction with SMAD3. Journal of Cell Science, 2018, 131, .	1.2	18
46	Chronic Interstitial Damage in Proteinuria. Kidney and Blood Pressure Research, 1999, 22, 47-52.	0.9	18
47	Eculizumab prevents thrombotic microangiopathy in patients with atypical haemolytic uraemic syndrome in a long-term observational study. CKJ: Clinical Kidney Journal, 2019, 12, 196-205.	1.4	16
48	c-Rel orchestrates energy-dependent epithelial and macrophage reprogramming in fibrosis. Nature Metabolism, 2020, 2, 1350-1367.	5.1	16
49	Regulation of Endothelial-to-Mesenchymal Transition by MicroRNAs in Chronic Allograft Dysfunction. Transplantation, 2019, 103, e64-e73.	0.5	15
50	MicroRNA antagonist therapy during normothermic machine perfusion of donor kidneys. American Journal of Transplantation, 2022, 22, 1088-1100.	2.6	15
51	The impact of donor and recipient common clinical and genetic variation on estimated glomerular filtration rate in a European renal transplant population. American Journal of Transplantation, 2019, 19, 2262-2273.	2.6	13
52	Dual MicroRNA Blockade Increases Expression of Antioxidant Protective Proteins: Implications for Ischemia-Reperfusion Injury. Transplantation, 2020, 104, 1853-1861.	0.5	13
53	MiR-126-3p Is Dynamically Regulated in Endothelial-to-Mesenchymal Transition during Fibrosis. International Journal of Molecular Sciences, 2021, 22, 8629.	1.8	13
54	The NF-ÎºB1 is a key regulator of acute but not chronic renal injury. Cell Death and Disease, 2017, 8, e2883-e2883.	2.7	12

#	Article	IF	Citations
55	Orthostatic intolerance is common in chronic disease â€" A clinical cohort study. International Journal of Cardiology, 2014, 174, 861-863.	0.8	11
56	Systematic assessment of the influence of complement gene polymorphisms on kidney transplant outcome. Immunobiology, 2016, 221, 528-534.	0.8	10
57	Obesity, Sex, Race, and Early Onset Hypertension. Hypertension, 2020, 76, 859-865.	1.3	10
58	Heparan sulfate in chronic kidney diseases: Exploring the role of 3-O-sulfation. Biochimica Et Biophysica Acta - General Subjects, 2019, 1863, 839-848.	1.1	9
59	Cell therapy during machine perfusion. Transplant International, 2021, 34, 49-58.	0.8	9
60	Biomarkers of acute injury: predicting the long-term outcome after transplantation. Kidney International, 2013, 84, 1072-1074.	2.6	8
61	Acute kidney injury electronic alerts: mixed methods Normalisation Process Theory evaluation of their implementation into secondary care in England. BMJ Open, 2019, 9, e032925.	0.8	8
62	Mycobacterium simiae: A Previously Undescribed Pathogen in Peritoneal Dialysis Peritonitis. American Journal of Kidney Diseases, 2005, 45, e75-e78.	2.1	7
63	Late allograft loss due to recurrence of pâ€ANCAâ€associated systemic vasculitis in a patient with relapsing polychondritis. Nephrology Dialysis Transplantation, 2001, 16, 1705-1707.	0.4	6
64	Patient stratification and therapy in atypical haemolytic uraemic syndrome (aHUS). Immunobiology, 2016, 221, 715-718.	0.8	6
65	The impact of severe acute kidney injury requiring renal replacement therapy on survival and renal function of heart transplant recipients â€" a UK cohort study. Transplant International, 2020, 33, 1650-1666.	0.8	6
66	Eculizumab (ECU) in Atypical Hemolytic Uremic Syndrome (aHUS) Patients with Progressing Thrombotic Microangiopathy (TMA): 2-Year Data.. Blood, 2012, 120, 2084-2084.	0.6	6
67	Anticoagulation and kidney injury: rare observation or common problem?. Journal of Nephrology, 2013, 26, 603-605.	0.9	6
68	Implementation of pre-clinical methodologies to study fibrosis and test anti-fibrotic therapy. Current Opinion in Pharmacology, 2019, 49, 95-101.	1.7	5
69	Comparison of the Outcome of Kidney Transplant After Pulsatile or Continuous ExÂVivo Hypothermic Machine Perfusion of Kidneys Donated After Cardiac Death: Analysis of Kidney Pairs. Transplantation Proceedings, 2019, 51, 1785-1790.	0.3	4
70	Eculizumab Is An Effective Long-Term Treatment In Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Resistant to Plasma Exchange/Infusion (PE/PI): Results of An Extension Study. Blood, 2011, 118, 193-193.	0.6	4
71	A Novel Role for Nephrin in the Maintenance of Glomerular Structure. Journal of the American Society of Nephrology: JASN, 2009, 20, 1661-1663.	3.0	2
72	Mechanisms of Renal Graft Chronic Injury and Progression to Interstitial Fibrosis. Current Transplantation Reports, 2015, 2, 259-268.	0.9	2

#	Article	IF	Citations
73	Modifying Renal Gene Expression by Anti-Sense Oligonucleotide Delivery during Normothermic Machine Perfusion. Transplantation, 2018, 102, S728.	0.5	2
74	Changing Protein Permeability with Nephron Loss: Evidence for a Human Remnant Nephron Effect. American Journal of Nephrology, 2019, 50, 152-159.	1.4	2
75	Motion correction of free-breathing magnetic resonance renography using model-driven registration. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2021, 34, 805-822.	1.1	2
76	Eculizumab Prevents Thrombotic Microangiopathy: Long-Term Follow-up Study of Patients with Atypical Hemolytic Uremic Syndrome. Blood, 2015, 126, 2252-2252.	0.6	2
77	IgA-associated renal diseases. Current Opinion in Nephrology and Hypertension, 1996, 5, 134-140.	1.0	1
78	Should Complement Activation Be a Target for Therapy in Renal Transplantation?. Journal of the American Society of Nephrology: JASN, 2008, 19, 2250-2251.	3.0	1
79	Complement Activation and Progression of Chronic Kidney Disease. Hong Kong Journal of Nephrology, 2009, 11, 41-46.	0.0	1
80	Behaviour of transplanted tumours and role of matching in rejection. Transplant Immunology, 2015, 32, 121-125.	0.6	1
81	Immunosuppression-induced clonal T-cell lymphoproliferative disease causing severe diarrhoea mimicking coeliac disease following renal transplantation: a case report. BMC Nephrology, 2020, 21, 220.	0.8	1
82	Compliments to the book on complement. Trends in Molecular Medicine, 1999, 5, 243.	2.6	0
83	Diabetic glomerular disease: pitfalls in diagnosis. CKJ: Clinical Kidney Journal, 2009, 2, 187-188.	1.4	0
84	MP178ISCHEMIA REPERFUSION INJURY INDUCES A PRO-FIBROTIC PHENOTYPE IN HUMAN PROXIMAL TUBULAR EPITHELIAL CELLS. Nephrology Dialysis Transplantation, 2016, 31, i400-i401.	0.4	0
85	Epigenetic regulators, including SETD7, as new targets for the treatment of chronic kidney disease. Lancet, The, 2016, 387, S66.	6.3	0
86	Successful virtual UK Kidney Week sees record-breaking registration. Journal of Kidney Care, 2020, 5, 290-291.	0.1	0